Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc.

Biotechnology • Healthcare • Foster City, CA, United States • TERN (NMS)

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

650 525 5535 1065 East Hillsdale Boulevard, Foster City, CA 94404, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Terns Pharmaceuticals stock soars after leukemia drug delivers big early responses in tough-to-treat patients - MSN
MSN • Dec 26
Terns Pharmaceuticals (TERN) Is Up 74.1% After Positive Phase 1 TERN-701 Data in CML Patients - Yahoo Finance
Yahoo Finance • Nov 4
Terns Pharmaceuticals (TERN) Stock Today (Dec. 18, 2025): Why Shares Are Sliding After the Rally, and What Analysts Forecast Next - ts2.tech
ts2.tech • Dec 18
Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors - The Motley Fool
The Motley Fool • Dec 3
Terns Pharmaceuticals stock falls after disappointing obesity drug results - Investing.com
Investing.com • Oct 21

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Terns Pharmaceuticals, Inc. had layoffs?
No layoff events have been recorded for Terns Pharmaceuticals, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Terns Pharmaceuticals, Inc. have?
Terns Pharmaceuticals, Inc. has approximately 59 employees.
What industry is Terns Pharmaceuticals, Inc. in?
Terns Pharmaceuticals, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Terns Pharmaceuticals, Inc. a publicly traded company?
Yes, Terns Pharmaceuticals, Inc. is publicly traded under the ticker symbol TERN on the NMS. The company has a market capitalization of approximately $4.52 billion.
Where is Terns Pharmaceuticals, Inc. headquartered?
Terns Pharmaceuticals, Inc. is headquartered in Foster City, CA, United States at 1065 East Hillsdale Boulevard, Foster City, CA 94404, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.